Federal

;

Follow-up letter to Delta on employee plan coverage of PrEP

Oct 1, 2025 | ,

In July, we wrote to you to urge you you to cover all PrEP medications and services without cost-sharing, and not to employ prior authorization for the purpose of steering employees to one PrEP drug or another, as is required of all non-grandfathered commercial insurance plans in the United States. On August 23, 2025, you replied, assuring us that the enrollee notice we had brought to your attention had been “sent inadvertently,” and that Delta would “cover all three formulations of PrEP without cost-sharing subject to the terms and conditions of the plans.”  Unfortunately, we now have learned that Delta Air Lines intends to impose prior authorization requirements to steer employees and their family members who use PrEP to the generic formulation of PrEP effective October 1, 2025.

read more

HIV Groups letter to CVS Health on not covering Yeztugo

Sep 18, 2025 | ,

We, the undersigned 64 organizations, on behalf of people and communities affected by HIV, their care providers, public health practitioners, and community-based organizations, write in response to statements made by CVS Health to the media that it does not intend to cover Yeztugo (lenacapavir), a twice-yearly long-acting injectable drug recently approved by the FDA as pre-exposure prophylaxis (PrEP) for the prevention of HIV.[1]  We urge you to reconsider this decision and cover Yeztugo without delay.

read more

Comment to HRSA on enrollment and re-certification of entities in the 340B drug pricing program

Sep 5, 2025 | ,

The HIV+Hepatitis Policy Institute submits this comment in support of HRSA’s proposed documentation and registration updates for Sexually Transmitted Disease (STD) grantees and subgrantees participating in the 340B Drug Pricing Program. STI clinics are a key setting for HIV testing and prevention services, including PrEP and PEP, as well as for testing and treatment for viral hepatitis, especially hepatitis C. As longstanding advocates for the 340B program, we believe strong oversight and clear documentation are critical to preserving its integrity and ensuring it continues to serve its core mission: supporting safety net providers and expanding access to care for low-income and underserved populations, including people with or at risk of HIV and hepatitis.

read more

Letter to Secretary Kennedy opposing changes to the PRWORA that limit testing, treatment, and prevention for communicable diseases

Aug 13, 2025 | ,

Thank you for the opportunity to comment on new guidance the Department of Health and Human Services has issued on the interpretation of “federal public benefits” under the Personal Responsibility and Work Opportunity Reconciliation Act (PRWORA). We oppose any changes that limit access to testing, treatment, and prevention for communicable diseases, including HIV and hepatitis. New limits on access by “non-qualified” immigrants to healthcare for the testing, treatment, or prevention of communicable disease endanger not just those individuals, but by allowing communicable diseases to go undiagnosed, untreated, and unprevented, increase transmission, raise prevalence, and endanger the health of everyone in the United States.

read more

Letter to Delta Air Lines on not covering a PrEP medication in employee insurance plans

Jul 21, 2025 | ,

We are extremely alarmed that Delta Air Lines has decided not to cover certain HIV Pre-Exposure Prophylaxis (PrEP) medications in some or all of its employee health plans, as required by law.  Attached to this letter is a notice sent to an enrollee indicating that Descovy, a daily oral PrEP drug, will no longer be covered by Delta’s health insurance plan beginning on August 1, 2025.  This change affects all enrollees (employees and their family members). 

read more

Pin It on Pinterest